Results 21 to 30 of about 786,314 (373)

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

Scientific Reports
Tafamidis is the world's first and only oral drug approved to treat the rare disease transthyretin amyloid cardiomyopathy (ATTR-CM). Medicines are known to have different adverse reactions during the course of treatment.
Fan Wu, He Zhu, Yue Zhang
doaj   +3 more sources

Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)

BMC Pharmacology and Toxicology, 2023
Background Osteonecrosis of the jaw (ONJ) is a rare but serious adverse drug reaction (ADR) commonly associated with bisphosphonate and denosumab therapy.
Hardeep S. Ahdi, T. Wichelmann, Sasirekha Pandravada, E. Ehrenpreis   +3 more
semanticscholar   +1 more source

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2023
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan   +8 more
semanticscholar   +1 more source

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

Frontiers in Immunology, 2023
Background Risankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and Crohn’s disease.
Yamin Shu, J. Chen, Yiling Ding, Qilin Zhang   +3 more
semanticscholar   +1 more source

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database

Frontiers in Endocrinology, 2022
Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly improved clinical effects on glycemic control. However, real-world data concerning the difference in gastrointestinal adverse events (AEs) among different GLP-1 RAs are ...
Lu Liu, Jia Chen, Lei Wang, C. Chen, Li Chen   +4 more
semanticscholar   +1 more source

Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system

Expert Opinion on Drug Safety, 2023
Migraine has a high prevalence in the population and accounts for 12% of primary headaches. Ubrogepant is used for the treatment of acute migraine, and although some clinical trials have demonstrated the safety of Ubrogepant, its long-term safety in a large sample of the population remains to be investigated. We collected data from the US Food and Drug
Bing, Cao, Shanshan, Gu, Zhisen, Shen, Yuna, Zhang, Yiming, Shen, Hang, Chen   +5 more
openaire   +2 more sources

A real‐world pharmacovigilance study of FDA adverse event reporting system events for sildenafil

Andrology, 2023
Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), is widely used for the treatment of erectile dysfunction (ED). However, the safety profile of sildenafil, including adverse event (AEs), requires comprehensive evaluation.
Y. Wang, Bin Zhao, Haiyan Yang, Zheng Wan   +3 more
semanticscholar   +1 more source

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System

Clinical Epidemiology, 2022
Background Olaparib, the world’s first poly ADP-ribose polymerase (PARP) inhibitor (PARPi), has been approved for treatment of ovarian cancer, breast cancer, pancreatic cancer and prostate cancer by FDA.
Yamin Shu, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang   +4 more
semanticscholar   +1 more source

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system

CNS Neuroscience & Therapeutics, 2023
Objective Quetiapine, an atypical second‐generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse ...
Yamin Shu, Yiling Ding, Lulu Liu, Qilin Zhang   +3 more
semanticscholar   +1 more source

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database

Frontiers in Pharmacology, 2023
Background: Sound drug safety information is important to optimize patient management, but the widely recognized comprehensive landscape of culprit-drugs that cause severe cutaneous adverse reactions (SCARs) is currently lacking.
Dongxuan Li, Jinghui Gou, Jun Zhu, Tongyan Zhang, Feng Liu, Daojun Zhang, Liyang Dai, Wenjun Li, Qinglong Liu, Chunmeng Qin, Qian Du, Songqing Liu   +11 more
semanticscholar   +1 more source